Deals
Madrigal Pharma Is Exploring Sale After Receiving Takeover Interest
- Drug developer is working with advisers at Centerview on sale
- A sale could attract other drugmakers with an interest in NASH
Photographer: John Guillemin/Bloomberg
This article is for subscribers only.
Madrigal Pharmaceuticals Inc., with just nine employees and a market value of about $4.3 billion, is exploring a sale after receiving takeover interest from other drugmakers eyeing treatments for a liver disease linked to obesity, people familiar with the matter said.
The West Conshohocken, Pennsylvania-based company is working with investment bank Centerview Partners Holdings on the potential sale, the people said, declining to be identified as the matter is private. The deliberations are at an early stage and Madrigal may opt to continue operations on its own, they said. The shares jumped in New York.